Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Hereditary hyperferritinemia-cataract syndrome in three Czech families: molecular genetic testing and clinical implications

J. Moravikova, T. Honzik, E. Jadvidzakova, K. Zdrahalova, R. Kremlikova Pourova, M. Korbasova, P. Liskova, L. Dudakova

. 2020 ; 24 (6) : 352.e1-352.e5. [pub] 20201119

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NV17-30500A MZ0 CEP Register

BACKGROUND: Hereditary hyperferritinemia-cataract syndrome (HHCS) is an autosomal dominant disorder manifesting with high serum ferritin levels and the formation of early-onset cataracts, with numerous small opacities, predominantly in the lens cortex. HHCS is caused by mutations in the iron-responsive element of the FTL gene. The aim of this study was to establish a molecular diagnosis in three Czech probands with suspected HHCS. METHODS: A complex ocular and systemic evaluation, including ferritin and iron measurements, was performed. The 5' untranslated region of FTL was directly sequenced in all available family members, followed by paternity testing in one family. RESULTS: Three different FLT pathogenic variants (c.-161C>T, c.-167C>T, and c.-168G>C) present in the heterozygous state were detected in each of the 3 probands. Two segregated with the disease phenotype within the families, but c.-167C>T occurred de novo (confirmed by paternity testing). Prior to establishing molecular diagnosis, two probands were misdiagnosed with hemochromatosis. One individual, aged 43 years, underwent phlebotomy; another, aged 8.5 years, was treated with the iron chelator deferasirox, leading to life-threatening acute hyperammonemia, without severe liver injury. CONCLUSIONS: Lack of family history does not exclude HHCS, because the pathogenic variant can arise de novo. Noncoding regions are often omitted from diagnostic gene panels, thus evading detection. Careful clinical evaluations and targeted genetic screening are important for avoiding potentially harmful treatments.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026381
003      
CZ-PrNML
005      
20211209092656.0
007      
ta
008      
211013s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jaapos.2020.07.014 $2 doi
035    __
$a (PubMed)33221470
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Moravikova, Jana $u Research Unit for Rare Diseases, Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
245    10
$a Hereditary hyperferritinemia-cataract syndrome in three Czech families: molecular genetic testing and clinical implications / $c J. Moravikova, T. Honzik, E. Jadvidzakova, K. Zdrahalova, R. Kremlikova Pourova, M. Korbasova, P. Liskova, L. Dudakova
520    9_
$a BACKGROUND: Hereditary hyperferritinemia-cataract syndrome (HHCS) is an autosomal dominant disorder manifesting with high serum ferritin levels and the formation of early-onset cataracts, with numerous small opacities, predominantly in the lens cortex. HHCS is caused by mutations in the iron-responsive element of the FTL gene. The aim of this study was to establish a molecular diagnosis in three Czech probands with suspected HHCS. METHODS: A complex ocular and systemic evaluation, including ferritin and iron measurements, was performed. The 5' untranslated region of FTL was directly sequenced in all available family members, followed by paternity testing in one family. RESULTS: Three different FLT pathogenic variants (c.-161C>T, c.-167C>T, and c.-168G>C) present in the heterozygous state were detected in each of the 3 probands. Two segregated with the disease phenotype within the families, but c.-167C>T occurred de novo (confirmed by paternity testing). Prior to establishing molecular diagnosis, two probands were misdiagnosed with hemochromatosis. One individual, aged 43 years, underwent phlebotomy; another, aged 8.5 years, was treated with the iron chelator deferasirox, leading to life-threatening acute hyperammonemia, without severe liver injury. CONCLUSIONS: Lack of family history does not exclude HHCS, because the pathogenic variant can arise de novo. Noncoding regions are often omitted from diagnostic gene panels, thus evading detection. Careful clinical evaluations and targeted genetic screening are important for avoiding potentially harmful treatments.
650    _2
$a apoferritiny $x genetika $7 D001052
650    12
$a katarakta $x diagnóza $x genetika $7 D002386
650    _2
$a lidé $7 D006801
650    12
$a hyperferritinemie $7 D000085583
650    _2
$a molekulární biologie $7 D008967
650    _2
$a mutace $7 D009154
650    _2
$a rodokmen $7 D010375
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Honzik, Tomas $u Research Unit for Rare Diseases, Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Jadvidzakova, Eva $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Zdrahalova, Katerina $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Kremlíková Pourová, Radka, $u Department of Biology and Medical Genetics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic $d 1980- $7 xx0160300
700    1_
$a Korbasova, Marta $u Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Liskova, Petra $u Research Unit for Rare Diseases, Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Dudakova, Lubica $u Research Unit for Rare Diseases, Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. Electronic address: lubica.dudakova@lf1.cuni.cz
773    0_
$w MED00007058 $t Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus $x 1528-3933 $g Roč. 24, č. 6 (2020), s. 352.e1-352.e5
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33221470 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211209092655 $b ABA008
999    __
$a ok $b bmc $g 1715180 $s 1146888
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 24 $c 6 $d 352.e1-352.e5 $e 20201119 $i 1528-3933 $m Journal of AAPOS $n J AAPOS $x MED00007058
GRA    __
$a NV17-30500A $p MZ0
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...